Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lenvatinib - AiViva BioPharma

Next Previous
Drug Profile

Lenvatinib - AiViva BioPharma

Alternative Names: AIV 007

Latest Information Update: 31 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AiViva BioPharma
  • Class Amides; Antineoplastics; Chlorobenzenes; Cyclopropanes; Eye disorder therapies; Phenyl ethers; Quinolines; Small molecules; Urea compounds
  • Mechanism of Action Platelet-derived growth factor alpha receptor antagonists; Proto-oncogene protein c-kit inhibitors; Proto-oncogene protein c-ret inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Diabetic macular oedema; Wet age-related macular degeneration
  • Preclinical Liver cancer
  • No development reported Benign prostatic hyperplasia

Most Recent Events

  • 24 Dec 2024 The First Affiliated Hospital of Zhengzhou University plans a phase Ib/II trial for Squamous cell cancer (Metastatic disease, Second-line therapy or greater, Late stage disease, Unresectable/Inoperable, Combination therapy) (IV) in January 2025 (NCT06746961, QLMA-EC-IIT-001)
  • 14 Nov 2024 Pharmacodynamics data from preclinical studies in Liver cancer presented at the 75th Annual Meeting of the American Association for the Study of Liver Diseases(AASLD-2024)
  • 14 Nov 2024 Pharmacodynamics data from preclinical studies in Liver cancer presented at the 75th Annual Meeting of the American Association for the Study of Liver Diseases

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top